SURVYR

IRD

Opus Genetics, Inc.
$3.68
+$0.22 (6.36%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-15%+40%+94%+149%+204%Oct 2025Oct 2026Apr 202652w low $1.70
IRDSPY
Wall St. Highest PT $20.00 (+443.5%) Wall St. Avg PT $13.47 (+266.0%)
$2$8$14$20$26POC $4Hi $20Avg $13
Underwater Drawdown %Max DD -49.2%Current -39.4%
0.0%-49.2%
Relative Strength vs SPY+70.1% vs SPYOutperforming
+221%0%-221%
1W
−$0.44 (10.68%)
1M
−$1.37 (27.13%)
3M
+$0.21 (6.05%)
6M
−$0.99 (21.20%)
YTD
+$1.67 (83.08%)
1Y
+$1.75 (90.67%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
18 analysts · mean score 1.17
1 = Strong Buy · 5 = Sell
Strong Buy317%
Buy1583%
Hold00%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$3.68
Average target$13.47
+$9.79 (+266.0%) upsideaverage target vs current price
CurrentAverageMedian
Low$8.00
Median$13.00
High$20.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-22 · Chardan Capital reiterated Buy on IRD
Reiterated
2026-10-16 · Citizens reiterated Market Outperform on IRD
Reiterated
2026-10-06 · Jones Trading reiterated Buy on IRD
Reiterated
2026-10-02 · Chardan Capital reiterated Buy on IRD
Reiterated
2026-09-10 · Wedbush reiterated Outperform on IRD
Reiterated
2026-09-09 · Oppenheimer reiterated Outperform on IRD
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$288.7M
P/E (next 12 months, estimated)-4.9
52-week range$1.70 – $7.07
Revenue growth (latest quarter vs a year ago)-73.8%
Dividend yieldNo dividend
Analyst consensusStrong Buy (17)
Average analyst price target$13.47 (+266%)

What they do

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for IRD yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

IRD earningsNext report in 14 days
Next report · quarter Sep 2026
Wed Nov 11, 2026Before the open
EPS consensus-$0.15 range -$0.21–-$0.09
Revenue consensus$2.1M 18 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.08est -$0.16+49.3%Above estimates
May 12, 2026-$0.75est -$0.14−448.8%Below estimates
Mar 10, 2026-$0.21est -$0.10−110.0%Below estimates
Nov 12, 2025-$0.25est -$0.13−92.3%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-25 12:00:22 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.750.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$755.0K-73.8%
2026-03-31$2.2M–
2025-12-31$3.9M–
2025-09-30$3.1M–
2025-06-30$2.9M–

News & catalysts

More news
Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval
Nasdaq · Oct 25
Rating changes
Reiterated
2026-10-22 · Chardan Capital reiterated Buy on IRD
Reiterated
2026-10-16 · Citizens reiterated Market Outperform on IRD
Reiterated
2026-10-06 · Jones Trading reiterated Buy on IRD
Reiterated
2026-10-02 · Chardan Capital reiterated Buy on IRD
Reiterated
2026-09-10 · Wedbush reiterated Outperform on IRD
Reiterated
2026-09-09 · Oppenheimer reiterated Outperform on IRD

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Magrath George
Director, Chief Executive Officer · 2026-10-23
Sell
$34.4K
Gagnon Robert E.
Chief Financial Officer · 2026-10-23
Sell
$49.6K
Yerxa Benjamin R
Director, President · 2026-10-23
Sell
$90.1K
Yerxa Benjamin R
Director, President · 2026-10-23
Sell
$27.2K
Schachle Joseph K
Chief Operating Officer · 2026-10-23
Sell
$17.0K
Foundation Fighting Blindness Retinal Degeneration Fund
Director · 2026-09-30
Sell
$2.8M
Gagnon Robert E.
Chief Financial Officer · 2026-09-03
Sell
$127.2K
Gagnon Robert E.
Chief Financial Officer · 2026-07-23
Sell
$22.9K
Magrath George
Director, Chief Executive Officer · 2026-07-23
Sell
$27.9K
Schachle Joseph K
Chief Operating Officer · 2026-07-23
Sell
$13.7K
Yerxa Benjamin R
Director, President · 2026-07-23
Sell
$22.1K
None
None · None
Sell
–

Stats refreshed 2026-10-25 12:00:22 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026